NCT06526624View on ClinicalTrials.gov

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

406

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

January 31, 2029

Conditions

Limited-stage Small-cell Lung Cancer

Interventions

DRUG

HS-20093

Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT06526624 - A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter